SCI Abstract

search
+
Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer
Advances in the understanding of the molecular biology of endometrial cancer have led to the incorporation of several targ...
Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression
Ovarian cancer (OC) remains the most fatal gynecological malignancy worldwide. Approximately 90 % of OC cases are of epith...
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary
ObjectiveCarcinosarcoma (CS) is a rare, aggressive malignancy characterized by high rates of extrauterine spread, frequent...
Quantifying opportunities to reduce high grade serous ovarian cancer via opportunistic salpingectomy
Ovarian cancer is a leading cause of cancer-related deaths among women. Although the incidence of ovarian cancer in the ge...
Treatment patterns and prognosis of patients with locally advanced vulvar cancer: a retrospective cohort study of the SEER database and a Chinese multicenter registry
BackgroundVulvar cancer is a rare gynecologic cancer with limited guideline consensus, particularly for locally advanced d...
Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study
Ovarian clear cell carcinoma (OCCC) is a distinct histologic subtype of epithelial ovarian cancer, comprising approximatel...
Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3001)
Endometrial cancer (EC) is the most common gynecological cancer worldwide [1]. In South Korea, EC surpassed other gynecolo...
Human fallopian tube epithelial organoids with TP53 mutation recapitulate features of serous tubal intraepithelial carcinoma (STIC)
Ovarian cancer (OC) is one of the most lethal gynecologic malignancies, with a 5-year survival rate of merely 50 % [1]. Du...
Survival impact of residual disease and timing of surgery in the management of advanced-stage low grade serous ovarian cancer: A systematic review and meta-analysis
Low-grade serous ovarian carcinoma (LGSOC) is a rare histologic subtype of ovarian cancer, which accounts for less than 10...
Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches
Following initial treatment for gynaecological cancer, patients transition to follow-up care [1,2]. This care has two main...
Corrigendum to ‘OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer’ [Gynecol Oncol 2025 Jun 197 182–191]
Volume 203, December 2025, Pages 182-183Author links open overlay panel, , , , , , , , , , , , , , , , , , , …View Abstrac...
Corrigendum to ‘HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study’ [Gynecologic Oncology 194 (2025) 33–40]
Volume 203, December 2025, Page 184Author links open overlay panelAlfonso Cortés-Salgado a c 1, Esther Moreno-Moreno b c 1...
Pathogenic germline variants among patients with ovarian cancer by self-reported ancestry: A commercial laboratory collaborative research registry study
Although the incidence and mortality of ovarian and tubal cancer, henceforth termed ovarian cancer (OC), have declined ove...
G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity
Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme that catalyzes poly (ADP-ribose) ribosylation in eukaryotic cells....
Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma
Volume 204, January 2026, Pages 17-22Author links open overlay panelRachel L. Furuya a 1, Whitney Grither a 1, Mark G. Eva...
The impact of cervical diameter on success of sentinel lymph node mapping in endometrial carcinoma: A retrospective cohort study
The replacement of lymphadenectomy with sentinel lymph node (SLN) mapping for the assessment of lymph node metastasis in e...
Effect of uterine manipulator on stage IB1 to IIA1 cervical cancer: A retrospective cohort study
Volume 204, January 2026, Pages 27-36Author links open overlay panel, , , , Highlights•Uterine manipulator use does not im...
Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?
Although rare, ovarian cancer (OC) remained the deadliest gynecologic cancer through 2024 in the US, only recently surpass...
Obstetric and perinatal outcomes following a diagnosis of gynecologic cancer during pregnancy
Volume 204, January 2026, Pages 44-51Author links open overlay panel, , , , , , Highlights•Diagnosis of gynecologic cancer...
AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer
Endometrial cancer is the only cancer with a worse survival rate over the past forty years [1]. Deaths due to endometrial ...
Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis
Anaplastic carcinoma of the ovary is a rare subtype of ovarian cancer. While incompletely understood, these cancers are kn...
Development and validation of an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population
Ovarian cancer is the most lethal gynecological malignancy, posing a significant threat to women's health. In 2020, approx...
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate
BackgroundMirvetuximab soravtansine-gynx (MIRV) is a FOLR1-binding antibody–drug conjugate (ADC) with a microtubule inhibi...
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Worldwide, ovarian cancer (OC) accounts for 314,000 diagnoses and >207,000 deaths annually [1]. No screening tests exis...
Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma
Volume 195, April 2025, Pages 34-44Author links open overlay panel, , , , , Highlights•CRISPR technology revolutionizes pr...
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies
Volume 195, April 2025, Pages 134-143Author links open overlay panel, , , , , , , Highlights•There is substantial impact o...
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers
Volume 195, April 2025, Pages 152-164Author links open overlay panel, , , Highlights•A substantial proportion of gynecolog...
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics
Volume 195, April 2025, Pages 180-191Author links open overlay panel, , Highlights•ADCs consist of a monoclonal antibody t...
MUTYH: Possibly another important gene in ovarian cancer?
Volume 196, May 2025, Pages 59-61Author links open overlay panel, , , Highlights•There is conflicting evidence on the risk...
Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028
Cervical cancer is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 de...
Load More
format_indent_increase